2024.08.13
On August 2, 2024, Beijing Imunopharm Technology Co., Ltd. ("Imunopharm"), an innovative enterprise focusing on the research and development of CAR-T cell therapies for hematologic malignancies and solid tumors, announced a commercial collaboration in mainland China with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (stock code: 000963.SZ, "Huadong Medicine"), with respect to its CD19-targeted, autologous CAR-T candidate, IM19 chimeric antigen receptor (CAR)-T cell injection ("IM19 Injection").
Imunopharm will grant Huadong Medicine exclusive commercialization rights to the IM19 Injection in mainland China and under the terms of the agreement, it will receive an upfront payment of RMB 125 million as well as potential additional regulatory and commercial milestone payments of up to RMB 950 million. Imunopharm will continue to be responsible for the development, registration and production of the IM19 Injection in mainland China.
JunHe was entrusted by Imunopharm to review, modify and negotiate the agreement for this project. JunHe’s team, with its consistently efficient and meticulous work style, and dedicated and professional service attitude, earned the trust and recognition of the client.
Partner CHEN, Jie led JunHe’s team in this project.
